TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06349473: A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia

Sponsor: Equilibra Bioscience LLC · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 31 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,540,880

Rescue Site Savings

+$1,015,580

Unlock Full NCT06349473 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06349473 Rescue Dossier →